NeuroOne(R) to Report Second Quarter Fiscal Year 2026 Financial Results on Tuesday, May 12 at 8:30 a.m. Eastern Time

April 28, 2026 at 08:30 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

EDEN PRAIRIE, MINN. - April 28, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2026, before market open on May 12, 2026.

Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Tuesday, May 12, 2026, to discuss the Company’s fiscal second quarter 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:

Fiscal Second Quarter 2026 Earnings Conference Call

Date: Tuesday, May 12, 2026

Time: 8:30 a.m. Eastern time

U.S. Dial-In (Toll Free): 888-506-0062

International Dial-In: 973-528-0011

Participant Access Code: 224785

Webcast: NMTC FY Q2 2026 Earnings Call Webcast

Please join at least five minutes before the start of the call to ensure timely participation.

A playback of the call will be available through Tuesday, May 26, 2026. To listen to the replay, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 53948. A webcast replay will also be available using the webcast link above through Wednesday, May 12, 2027.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

View the original release on www.newmediawire.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article